Hull Hans

Chief Business Officer at PLRX; SVP, Business Operations at Avalanche Biotechnologies, Inc.

Sold, on record
$3.1M
Dollars the filings state
Form 4 sales
10
Latest Jan 17, 2025
Form 144 notices
1
Proposed sales
Companies
2
Filed as an executive or holder

Companies

Sales by reason

0
Routine
0
Plan not stated
0
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. 1 Form 4 sale PLRXPlan not stated
    Dec 20, 2022 2022

    Sold 8,748 shares at $19.10 ($167k)

    Hull Hans, Chief Business Officer

    Sold 6% of holdings ($2.8M position)138,191 shares leftFirst sale on recordFiling

  2. 2 Form 4 sale PLRXRoutine
    Mar 30, 2023 +100 days

    Sold 9,036 shares at $26.52 ($240k)

    Hull Hans, Chief Business Officer

    10b5-1 planSold 4.3% of holdings ($5.6M position)201,964 shares leftFiling

  3. 3 Form 4 sale PLRXRoutine
    Jul 17, 2023 +109 days

    Sold 17,937 shares at $18.01 ($323k)

    Hull Hans, Chief Business Officer

    10b5-1 planSold 7.6% of holdings ($4.3M position)219,183 shares leftFiling

  4. 4 Form 144 notice PLRXNotice
    Aug 3, 2023 +17 days

    Filed to sell 34,919 shares ($660k)

    Hull Hans, Officer

    10b5-1 plan3.9x usual sizeFiling

  5. 5 Form 4 sale PLRXUnusual
    Aug 4, 2023 +1 day

    Sold 33,119 shares at $20.01 ($663k)

    Hull Hans, Chief Business Officer

    10b5-1 planSold 14.5% of holdings ($4.6M position)194,855 shares left3.7x usual sizeFollows a Form 144Filing

  6. 6 Form 4 sale PLRXRoutine
    Jan 17, 2024 +166 days

    Sold 9,786 shares at $17.23 ($169k)

    Hull Hans, Chief Business Officer

    10b5-1 planSold 5% of holdings ($3.4M position)185,069 shares left0.7x usual sizeFiling

  7. 7 Form 4 sale PLRXRoutine
    Jul 10, 2024 +175 days

    Sold 9,900 shares at $11.56 ($114k)

    Hull Hans, Chief Business Officer

    10b5-1 planSold 4.2% of holdings ($2.7M position)227,494 shares left1x usual sizeFiling

  8. 8 Form 4 sale PLRXRoutine
    Jan 17, 2025 +191 days

    Sold 15,936 shares at $11.20 ($178k)

    Hull Hans, Chief Business Officer

    10b5-1 planSold 7% of holdings ($2.5M position)211,558 shares left1.6x usual sizeFiling

Every transaction

Loading transactions…

Sales and notices (11)

Form 144 notices and Form 4 sales by Hull Hans
Source
Jan 17, 2025Jan 22, 2025PLRXChief Business OfficerForm 4 sale15,936$178k7.0%RoutineSEC
Jul 10, 2024Jul 12, 2024PLRXChief Business OfficerForm 4 sale9,900$114k4.2%RoutineSEC
Jan 17, 2024Jan 19, 2024PLRXChief Business OfficerForm 4 sale9,786$169k5.0%RoutineSEC
Aug 4, 2023Aug 7, 2023PLRXChief Business OfficerForm 4 sale33,119$663k14.5%UnusualSEC
Aug 3, 2023Aug 3, 2023PLRXOfficerForm 144 notice34,919$660kNoticeSEC
Jul 17, 2023Jul 19, 2023PLRXChief Business OfficerForm 4 sale17,937$323k7.6%RoutineSEC
Mar 30, 2023Apr 3, 2023PLRXChief Business OfficerForm 4 sale9,036$240k4.3%RoutineSEC
Dec 20, 2022Dec 21, 2022PLRXChief Business OfficerForm 4 sale8,748$167k6.0%Plan not statedSEC
Jun 4, 2015Jun 5, 2015Avalanche Biotechnologies, Inc.SVP, Business OperationsForm 4 sale2,000$75k15.0%Plan not statedSEC
May 4, 2015May 6, 2015Avalanche Biotechnologies, Inc.SVP, Business OperationsForm 4 sale5,000$154k30.6%UnusualSEC
Apr 7, 2015Apr 8, 2015Avalanche Biotechnologies, Inc.SVP, Business OperationsForm 4 sale27,500$1.1M89.2%UnusualSEC